INTERNATIONAL | U.S.
Careers
Contact Us
About us
Products
News, Press & Events
Visit this section
Visit this section
Explore our news

Veryan Design Intelligence:
imagination + intuition + innovation

Our Vision

'We exist to improve patient care and quality of life through imagination, intuition and innovation'

 

Our Purpose

‘Transforming lives through design intelligence’

BioMimics-3D® Vascular Stent System

The BioMimics-3D Vascular Stent System has a unique 3D helical geometry which imparts a gentle helical shape to the stented artery.

Read more
MIMICS-2 3-year data released

Professor Thomas Zeller PI of the MIMICS-2 IDE study has announced that the freedom from CDTLR at 3 years for the BioMimics 3D stent was 81%, which is comparable to the outcomes for DCB, DES and Supera, despite treating more challenging lesions and without the need for lesion preparation.

Read more
Veryan & Otsuka

Veryan was founded in 2005 as the result of a technology spin out from Imperial College, London.

Read more

The Latest from Veryan

News, updates and press releases

Board Announcement – Appointment of new CEO

HORSHAM, UK – 01 SEPTEMBER 2022 – The Board of Veryan Holdings Ltd announces that, following 11 years of service, including 8 years as COO and 3 years as CEO, Nick Yeo has decided to leave Veryan to pursue new professional and personal goals.

Read more
Veryan Medical and Premier collaboration

HORSHAM, UK – 01 MAY 2022 – Veryan Medical Inc. has been awarded a group purchasing agreement for Peripheral and Biliary Stents with Premier, Inc. Effective 01 May 2022, the new agreement allows Premier members, at their discretion, to take advantage of special pricing and terms pre-negotiated by Premier for the BioMimics 3D Vascular Stent System.

Read more
MIMICS-3D EU 3-year results

Veryan Medical has confirmed the release at ISET 22 of the MIMICS-3D EU 3-year results by the study PI Michael Lichtenberg MD. MIMICS-3D EU is a prospective, multicentre, observational registry to evaluate the BioMimics 3D Vascular Stent System. The study evaluated safety, effectiveness and device performance within a real-world clinical population of 507 patients enrolled in 23 pan-European sites.

Read more

Get in touch

Find contact details and send us a message.

Contact us